Ashwani Verma

Stock Analyst at UBS

(2.27)
# 2,667
Out of 4,911 analysts
73
Total ratings
42.31%
Success rate
-0.2%
Average return

Stocks Rated by Ashwani Verma

Exelixis
Jul 11, 2025
Maintains: Neutral
Price Target: $38$43
Current: $45.60
Upside: -5.70%
Neurocrine Biosciences
Jul 9, 2025
Maintains: Buy
Price Target: $152$174
Current: $132.14
Upside: +31.68%
Legend Biotech
Jul 2, 2025
Maintains: Buy
Price Target: $60$54
Current: $43.36
Upside: +24.54%
United Therapeutics
Jun 30, 2025
Maintains: Buy
Price Target: $410$385
Current: $304.50
Upside: +26.44%
Teva Pharmaceutical Industries
Jun 26, 2025
Maintains: Buy
Price Target: $24$23
Current: $16.54
Upside: +39.06%
Alkermes
Jun 17, 2025
Upgrades: Buy
Price Target: $33$42
Current: $26.13
Upside: +60.73%
Incyte
Jun 3, 2025
Maintains: Neutral
Price Target: $61
Current: $70.20
Upside: -13.11%
Cytokinetics
May 2, 2025
Maintains: Neutral
Price Target: $47$41
Current: $37.18
Upside: +10.27%
Harmony Biosciences Holdings
Apr 28, 2025
Maintains: Buy
Price Target: $55$48
Current: $37.52
Upside: +27.93%
ACADIA Pharmaceuticals
Apr 28, 2025
Maintains: Buy
Price Target: $25$22
Current: $23.25
Upside: -5.38%
Maintains: Neutral
Price Target: $1.5$1.05
Current: $1.04
Upside: +0.96%
Upgrades: Buy
Price Target: $145$179
Current: $118.23
Upside: +51.40%
Maintains: Buy
Price Target: $22$14
Current: $11.03
Upside: +26.93%
Maintains: Buy
Price Target: $106$114
Current: $71.31
Upside: +59.87%
Maintains: Buy
Price Target: $55$54
Current: $13.50
Upside: +300.00%
Maintains: Buy
Price Target: $107$105
Current: $100.83
Upside: +4.14%
Downgrades: Neutral
Price Target: $28
Current: $36.67
Upside: -23.64%
Maintains: Buy
Price Target: $11$7
Current: $100.14
Upside: -93.01%
Upgrades: Neutral
Price Target: $9$12
Current: $9.41
Upside: +27.52%
Initiates: Buy
Price Target: $15
Current: $0.53
Upside: +2,719.55%